SUMMARY
This report on the real life use of luspatercept in Belgium, describes data of 77 patients. In the response analysis, 65.8% showed a response to treatment, including 35.4% that reached transfusion independency for a minimum of eight weeks. In the responding group, the duration of treatment was at least 38 weeks in 75% of patients. Reasons to stop treatment were adverse event (16,3%), death (23,3%), no response (34,9%) and disease progression (25,6%). One patient stopped treatment due to pronounced fatigue although having an erythroid response. These data confirm the efficacy of luspatercept and the need for real-life data on quality of life.
(BELG J HEMATOL 2025;16(2):65–9)